Lilly expects to launch four new medicines by 2023 end with Mounjaro for type II diabetes already launched and cancer drug Jaypirca already approved. Mounjaro is off to a solid start. However, the CRL for donanemab and mirikizumab will probably delay potential launch of the candidates by several months. Generic competition for several drugs, rising pricing pressure in the United States mainly on key drug, Trulicity, and price cuts in some international markets like China, Japan and Europe are a few top-line headwinds. Estimates have gone up slightly ahead of Q1 results.